SCHEMBL25265196

SCHEMBL25265196

C1=CC(c2ccc(OCc3ccccc3)cc2)Oc2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
PTGS1 P23219 1/20 0.44
SLC6A2 P23975 1/20 0.44
CYP2C19 P33261 1/20 0.44
PTGS2 P35354 1/20 0.44
SLC6A3 Q01959 1/20 0.44
HIF1A Q16665 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
MAOB P27338 6/20 0.43
MAOA P21397 2/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CA2 P00918 2/20 0.42
CA5A P35218 1/20 0.42
BCHE P06276 1/20 0.41
NR4A1 P22736 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25188259 1.00 LMNA (0.44) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL24983856 0.82 NFKB1 (0.43) SLC6A2SLC6A3MAOBMAPTL3MBTL1
SCHEMBL25190606 0.81 NFKB1 (0.42) LMNACYP1A2CYP2C19MAOBGAA
SCHEMBL25190608 0.81 NFKB1 (0.42) LMNACYP1A2CYP2C19MAOBGAA
SCHEMBL8550039 0.81 TNKS2 (0.47) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL3672681 0.80 CA2 (0.50) MAOBMAOARAB9ASMN1; SMN2CA2
SCHEMBL30315348 0.79 NFKB1 (0.38) CYP2C19MAOBMAPT
SCHEMBL17227883 0.79 NFKB1 (0.38) CYP2C19MAOBMAPT
SCHEMBL10653876 0.79 NFKB1 (0.53) PTGS2MAOBMAOAMAPTRAB9A
SCHEMBL25187435 0.79 NFKB1 (0.53) PTGS2MAOBMAOAMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11952358-B2 Flavan-3-ol analogs and anti-inflammatory activity HONG KONG BAPTIST UNIVERSITY (CN) 2024-04-09 US disclosed
US-20230159482-A1 FLAVAN-3-OL ANALOGS AND ANTI-INFLAMMATORY ACTIVITY HONG KONG BAPTIST UNIVERSITY (CN) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11952358-B2 Flavan-3-ol analogs and anti-inflammatory activity IL1A, IL6, IL1B LMNA 1569/4885CYP1A2 904/4885PTGS1 20/4885
US-20230159482-A1 FLAVAN-3-OL ANALOGS AND ANTI-INFLAMMATORY ACTIVITY IL1A, IL6, IL1B LMNA 1569/4885CYP1A2 904/4885PTGS1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.